A recent study identifies Neural EGFL-like 2 (NELL2), a secreted protein, as a key regulator of bone homeostasis, offering potential therapeutic applications for osteoporosis. NELL2 promotes ...
Cell- and animal-based models of bone formation reveal novel mechanisms involved in the cartilage-to-bone phenotype ...
A recent study identifies Neural EGFL-like 2 (NELL2), a secreted protein, as a key regulator of bone homeostasis, offering potential therapeutic applications for osteoporosis. NELL2 promotes ...
(A, B) ALP staining and activity detection were performed after treating cells with APPswe or BMP2 for 5 days or 7 days. (C, D) ARS staining and semiquantitative analysis were used to detect calcium ...
Drug trial shows reduced abnormal bone formation in those with fibrodysplasia ossificans progressiva
As flare-ups often precede the formation of new lesions, we are encouraged that this investigational drug may help prevent the progression of FOP. "The loss of mobility created by the abnormal bone ...
Researchers have shown that a naturally occurring peptide (small protein) holds promise as a new therapeutic for osteoporosis and other disorders that feature bone loss, with distinct advantages over ...
Experiments conducted in Brazil using laboratory rats have shown that graphene-based structures can act as a powerful ally in ...
A new small molecule could treat and prevent excess bone formation. Fibrodysplasia ossificans progressiva (FOP) is an extremely rare disease estimated to affect about one in 2 million people worldwide ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results